The best method for preventing seasonal influenza is to be vaccinated every pre-winter. The reason that individuals are encouraged to get vaccinated every year is on the grounds that influenza virus can cause severe disease. One of the problems is that there is a wide range of influenza viruses circulating the world over and which ones circulate changes time.
Every year, pharmaceutical organizations produce vaccines against the influenza infections predicted to be dominant during the upcoming influenza season. From year to year how well the vaccine works changes because of how much the circulating influenza viruses evolve between the time that the vaccine is produced and the start of the influenza season. Therefore, in many years, seasonal influenza vaccine is 50 to 70 percent effective.
During the Australian 2017 influenza season, this season’s influenza vaccine was just 10 percent effective because of the emergence of variation H3N2 that was “vaccine-resistant “. Researchers from UTMB and Biomed Protection have published this prediction very nearly two years ahead of time showing that the prediction of influenza vaccine efficacy might be possible.
In their study, they predicted which H3N2 variations would progress toward becoming “vaccine-resistant”, and this prediction has been presently approved during the 2017 Australian influenza season.
Slobodan Paessler, UTMB professor in the department of pathology said, “It’s essential consistently that we monitor the Australian influenza season because the following influenza season in the U.S. and Europe could be comparative”.
“In Australia, U.S. and, European authorities experts prepare for a potentially severe influenza season, when the flu vaccine isn’t terribly effective.” In the new paper published in F1000 Research, Paessler and Veljko Velkovic, co-founder of Biomed Protection, utilized the same bioinformatics platform to determine how well the current seasonal influenza vaccine may protect against H3N2 influenza viruses isolated in the U.S and Australia amongst July and September 2017. Virus gene sequences currently circulating strains were obtained from the Global Initiative on Sharing All Influenza Database.
The outcomes distributed suggest that the current influenza vaccine will work better during the 2018 U.S. influenza season than the 2017 Australian influenza season.
In Australia H3N2 of two groups of viruses circulating, and the vaccine was projected to protect against the minority of viruses however not the majority part viruses. In the U.S., the vaccine is projected to be effective against the majority H3N2 influenza viruses up until this point. The U.S. Centers for Disease Control laboratory has published a report demonstrating that this flu vaccine is like the influenza viruses afflicting individuals in the U.S. this season, recommending that influenza vaccine should offer comparable protection as past seasons.
Veljkovic and Paessler said, “In any case, this situation could change if any of the viruses from the minority group, which isn’t covered by the vaccine, were to become dominant”.
“Consequently, its vital that we closely monitor the evolution of the H3N2 influenza viruses all through the 2018 U.S. influenza season.”
Recently, lack of effectiveness in this effectiveness has been connected to a particular mutation generated during the vaccine production process. Paessler and Veljkovic analyzed the effect of the mutation and found that it is shifting the vaccine virus from the majority group to the minority group, potentially reducing the vaccine’s effectiveness.